Confo Therapeutics

Recent Finacing

Series B

Recent Raise

$65.1M

Confo Therapeutics develops Confo® ConfoBody single-domain antibodies to stabilize GPCR conformations for discovery of small-molecule modulators and agonistic antibodies, operating drug and target discovery centers in Ghent and Brussels.

Founded 2015

Brussels Hoofdstedelijk Gewest, Belgium

51-100

Private

confotherapeutics.com

Highlights

Focus Areas

Biotechnology

Health Care

Medical

Therapeutics

Recent Investors

M

Financials

$100.4M

Total Raised

3

Funding rounds

15

Investors

Team

Upgrade to view the team

See the team members at Confo Therapeutics.